Clinical implications of CES2 RNA expression in neuroblastoma

Journal of Pediatric Surgery

Volumn 48, Issue 3, 2013, Pages 502-509

  Uchida, Keiichi ^a   Otake, Kohei ^a   Tanaka, Koji ^a   Hashimoto, Kiyoshi ^a   Saigusa, Susumu ^a   Matsushita, Kohei ^a   Koike, Yuhki ^a   Inoue, Mikihiro ^a   Ueeda, Motoko ^a   Okugawa, Yoshinaga ^a   Inoue, Yasuhiro ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Carboxylesterase 2; Irinotecan; Neuroblastoma; Prognosis

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 2; RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TUMOR CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEUROBLASTOMA; RNA; TUMOR CELLS, CULTURED;

EID: 84875171705     PISSN: 00223468     EISSN: 15315037     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2012.10.004     Document Type: Article

References (49)

1. E.V. Pindel, N.Y. Kedishvili, and T.L. Abraham Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin J Biol Chem 272 1997 14769 14775 (Pubitemid 27251744)
2. R. Humerickhouse, K. Lohrbach, and L. Li Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2 Cancer Res 60 2000 1189 1192 (Pubitemid 30151980)
3. P.D. Senter, K.S. Beam, and B. Mixan Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug Bioconjug Chem 12 2001 1074 1080 (Pubitemid 33136881)
4. W. Zhang, G. Xu, and H.L. McLeod Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis Appl Immunohistochem Mol Morphol 10 2002 374 380 (Pubitemid 35453699)
5. G. Xu, W. Zhang, and M.K. Ma Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan Clin Cancer Res 8 2002 2605 2611 (Pubitemid 34856347)
6. H.M. Dodds, M.C. Haaz, and J.F. Riou Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38 J Pharmacol Exp Ther 286 1998 578 583 (Pubitemid 28318036)
7. L.B. Saltz Irinotecan in the first-line treatment of colorectal cancer Oncology (Williston Park) 12 1998 54 58 (Pubitemid 28518489)
8. L.B. Saltz Irinotecan: a new agent comes of age Oncologist 6 2001 65 (Pubitemid 32155816)
9. U. Vanhoefer, A. Harstrick, and W. Achterrath Irinotecan in the treatment of colorectal cancer: clinical overview J Clin Oncol 19 2001 1501 1518 (Pubitemid 32202559)
10. H. Komuro, P. Li, and Y. Tsuchida Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma Med Pediatr Oncol 23 1994 487 492 (Pubitemid 24326458)
11. G. Vassal, M.J. Terrier-Lacombe, and M.C. Bissery Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts Br J Cancer 74 1996 537 545 (Pubitemid 26279047)
12. S. Blaney, S.L. Berg, and C. Pratt A phase I study of irinotecan in pediatric patients: a pediatric oncology group study Clin Cancer Res 7 2001 32 37 (Pubitemid 32110202)
13. T. Hirota, N. Kawai, and S. Kitagawa et al Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma Gan To Kagaku Ryoho 28 2001 2049 2054
14. H. Mugishima, T. Matsunaga, and K. Yagi Phase I study of irinotecan in pediatric patients with malignant solid tumors J Pediatr Hematol Oncol 24 2002 94 100 (Pubitemid 34150547)
15. B.H. Kushner, K. Kramer, and S. Modak Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma Cancer 103 2005 858 862 (Pubitemid 40216416)
16. T. Shitara, A. Shimada, and R. Hanada Irinotecan for children with relapsed solid tumors Pediatr Hematol Oncol 23 2006 103 110 (Pubitemid 43170531)
17. T. Satoh, M. Hosokawa, and R. Atsumi Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase Biol Pharm Bull 17 1994 662 664 (Pubitemid 24186112)
18. M.K. Danks, C.L. Morton, and E.J. Krull Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy Clin Cancer Res 5 1999 917 924 (Pubitemid 29180845)
19. P.M. Potter, J.S. Wolverton, and C.L. Morton In situ subcellular localization of epitope-tagged human and rabbit carboxylesterases Cytometry 32 1998 223 232 (Pubitemid 28286000)
20. S. Guichard, C. Terret, and I. Hennebelle CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues Br J Cancer 80 1999 364 370 (Pubitemid 29213186)
21. R. Khanna, C.L. Morton, and M.K. Danks Proficient metabolism of irinotecan by a human intestinal carboxylesterase Cancer Res 60 2000 4725 4728
22. M.H. Wu, B. Yan, and R. Humerickhouse Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells Clin Cancer Res 8 2002 2696 2700 (Pubitemid 34856359)
23. K. Ohtsuka, S. Inoue, and M. Kameyama Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer Lung Cancer 41 2003 187 198 (Pubitemid 36842782)
24. H. Yano, S. Kayukawa, and S. Iida Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma Cancer Sci 99 2008 2309 2314
25. Y. Inoue, C. Miki, and H. Watanabe Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line J Gastroenterol 41 2006 1149 1157 (Pubitemid 46487205)
26. J.J. Tumilowicz, W.W. Nichols, and J.J. Cholon Definition of a continuous human cell line derived from neuroblastoma Cancer Res 30 1970 2110 2118
27. T. Matsumura, T. Sugimoto, and T. Sawada Cell surface membrane antigen present on neuroblastoma cells but not fetal neuroblasts recognized by a monoclonal antibody (KP-NAC8) Cancer Res 47 1987 2924 2930 (Pubitemid 17113437)
28. M.A. Mena, J. Garcia de Yebenes, and A. Dwork Biochemical properties of monoamine-rich human neuroblastoma cells Brain Res 486 1989 286 296 (Pubitemid 19135139)
29. T. Sugimoto, Y. Horii, and T. Hino Differential susceptibility of HLA class II antigens induced by gamma-interferon in human neuroblastoma cell lines Cancer Res 49 1989 1824 1828 (Pubitemid 19108411)
30. A. Shikata, T. Sugimoto, and H. Hosoi Increased expression of trk proto-oncogene by gamma-interferon in human neuroblastoma cell lines Jpn J Cancer Res 85 1994 122 126 (Pubitemid 24074534)
31. R.R. Kisenge, H. Toyoda, and J. Kang Expression of short-form caspase 8 correlates with decreased sensitivity to Fas-mediated apoptosis in neuroblastoma cells Cancer Sci 94 2003 598 605 (Pubitemid 36975014)
32. M. Kaneko, Y. Tsuchida, and J. Uchino Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma J Pediatr Hematol Oncol 21 1999 190 197 (Pubitemid 30306029)
33. K. Tanaka, K. Otake, and Y. Mohri Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer Oncol Rep 21 2009 1489 1494
34. K.E. Bijwaard, N.S. Aguilera, and Y. Monczak Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma Clin Chem 47 2001 195 201 (Pubitemid 32142916)
35. J.M. Bland, and D.G. Altman Survival probabilities (the Kaplan-Meier method) BMJ 317 1998 1572 (Pubitemid 128719735)
36. J.M. Maris Recent advances in neuroblastoma N Engl J Med 362 2010 2202 2211
37. K. Otake, K. Uchida, and K. Tanaka HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma Pediatr Surg Int 27 2011 217 223
38. V. Pavillard, C. Agostini, and S. Richard Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines Cancer Chemother Pharmacol 49 2002 329 335 (Pubitemid 34253272)
39. S.P. Sanghani, S.K. Quinney, and T.B. Fredenburg Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis Clin Cancer Res 9 2003 4983 4991 (Pubitemid 37323305)
40. S. Marsh, M. Xiao, and J. Yu Pharmacogenomic assessment of carboxylesterases 1 and 2 Genomics 84 2004 661 668 (Pubitemid 39310943)
41. H. Zitzelsberger, U. Kulka, and L. Lehmann Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization Virchows Arch 433 1998 297 304 (Pubitemid 28477029)
42. E.A. Rakha, S.E. Pinder, and E.C. Paish Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis J Pathol 203 2004 754 761 (Pubitemid 38961561)
43. A.J. Zendman, I.M. Cornelissen, and U.H. Weidle TM7XN1, a novel human EGF-TM7-like cDNA, detected with mRNA differential display using human melanoma cell lines with different metastatic potential FEBS Lett 446 1999 292 298 (Pubitemid 29132746)
44. B.E. Stranger, M.S. Forrest, and M. Dunning Relative impact of nucleotide and copy number variation on gene expression phenotypes Science 315 2007 848 853
45. C.A. Pawlik, R.V. Iyengar, and E.J. Krull Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11 Mol Ther 1 2000 457 463
46. M.K. Danks, K.J. Yoon, and R.A. Bush Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma Cancer Res 67 2007 22 25 (Pubitemid 46142755)
47. G. Vassal, F. Doz, and D. Frappaz A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors J Clin Oncol 21 2003 3844 3852 (Pubitemid 46606240)
48. L. Bomgaars, J. Kerr, and S. Berg A phase I study of irinotecan administered on a weekly schedule in pediatric patients Pediatr Blood Cancer 46 2006 50 55 (Pubitemid 41779317)
49. L.R. Bomgaars, M. Bernstein, and M. Krailo Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 25 2007 4622 4627 (Pubitemid 350035322)